金凯生科(301509.SZ)发布上半年业绩，归母净利润7176.06万元，增长123.61%

Core Viewpoint - Jinkai Biotechnology (301509.SZ) reported a significant increase in both revenue and net profit for the first half of 2025, indicating strong financial performance and growth potential [1] Financial Performance - The company's operating revenue reached 348 million yuan, representing a year-on-year growth of 32.98% [1] - The net profit attributable to shareholders was 71.76 million yuan, showing a remarkable year-on-year increase of 123.61% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 59.17 million yuan, reflecting a year-on-year growth of 141.51% [1] - Basic earnings per share stood at 0.6 yuan [1]